Abstract
1. Stop injection/infusion immediately
2. Get extravasation kit
3. Put on (sterile) gloves
4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Original articles
Slevin ML, Piall EM, Aherne GW, et al: Subcutaneous infusion of cytosine arabinoside: a practical alternative to intravenous infusion. Cancer Chemother Pharmacol 10: 112–114, 1983.
Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.
Secondary literature
Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.
Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxic-drug extravasation: guidelines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.
Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.
Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.
Pharmacia & Upjohn, personal communication, November 1998.
Gain M, Melzer S, Meyer-Jürshof A, et al: Cytarabin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 3: 42, 1998.
Schneider G: Paravasate von Zytostatika. Diagnostik und -Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.
Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 1, 2nd edition: A42–44, 1997.
Summary of product characteristics Alexan® (Austria), Ebewe, June 2003.
Dorr RT, Von Hoff DD: Drug monographs: cytarabine. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. -Appleton & Lange, 2nd edition: 332–340, 1994.
Barth J: Paravasate und deren Behandlung. In: Barth J (ed) Zytostatika-Herstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.
Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.
Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.
Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 321: 327–335, 2001.
Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14: 212–216, 2002.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Cytarabine. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_23
Download citation
DOI: https://doi.org/10.1007/978-3-211-88893-3_23
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-88889-6
Online ISBN: 978-3-211-88893-3
eBook Packages: MedicineMedicine (R0)